Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.62 |
| ▸ | NOS3 | P29474 | 4/20 | 0.47 |
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | NOS2 | P35228 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | BHMT | Q93088 | 6/20 | 0.47 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ARG1 | P05089 | 1/20 | 0.43 |
| ▸ | ARG2 | P78540 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racemethionine SCHEMBL8902674 | 1.00 | GSR (0.62) | GSRNOS3NOS1NOS2CYP2C19 | |
| Lysine SCHEMBL938951 | 0.95 | GSR (0.71) | GSRNOS3NOS1NOS2CYP2C19 | |
| Lysine SCHEMBL1345092 | 0.95 | GSR (0.71) | GSRNOS3NOS1NOS2CYP2C19 | |
| Lysine SCHEMBL8720001 | 0.95 | GSR (0.71) | GSRNOS3NOS1NOS2CYP2C19 | |
| Lysine SCHEMBL1345091 | 0.95 | GSR (0.71) | GSRNOS3NOS1NOS2CYP2C19 | |
| Lysine SCHEMBL10491088 | 0.95 | GSR (0.71) | GSRNOS3NOS1NOS2CYP2C19 | |
| Lysine SCHEMBL27480207 | 0.95 | GSR (0.71) | GSRNOS3NOS1NOS2CYP2C19 | |
| Lysine SCHEMBL6665159 | 0.93 | GSR (0.69) | GSRNOS3NOS1NOS2CYP2C19 | |
| Lysine SCHEMBL6574898 | 0.93 | GSR (0.69) | GSRNOS3NOS1NOS2CYP2C19 | |
| Lysine SCHEMBL6574892 | 0.93 | GSR (0.69) | GSRNOS3NOS1NOS2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499303-A4 | MULTI-PHASE, MULTI-COMPARTMENT CAPSULAR SYSTEM | MILLER FRED H (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1499303-A2 | MULTI-PHASE, MULTI-COMPARTMENT CAPSULAR SYSTEM | Miller, Fred H. (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003086267-A2 | MULTI-PHASE, MULTI-COMPARTMENT CAPSULAR SYSTEM | MILLER FRED H (US) | 2003-10-23 | — | — | WO | disclosed |
| US-5593970-A | ANTITUMOR AND ANTCARCINOGENIC AGENTS; TRETMENT OF CANCEROUS BONE MARROW BEFORE REGRAFTING | BIOCHEM PHARMA INC. (CA) | 1997-01-14 | — | — | US | disclosed |